Immunization of patients with bleeding disorders

被引:26
作者
Makris, M
Conlon, CP
Watson, HG
机构
[1] Royal Hallamshire Hosp, Sheffield Haemophilia & Thrombosis Ctr, Sheffield S10 2JF, S Yorkshire, England
[2] John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England
[3] Aberdeen Royal Infirm, Dept Haematol, Aberdeen, Scotland
关键词
bleeding disorder; haemophilia; immunization; vaccination;
D O I
10.1046/j.1365-2516.2003.00819.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The immunization of patients with bleeding disorders differs from that of the normal population with respect to the risk of haematoma formation at the vaccination site and the unusual infective risks associated with the potential, and past, exposure to blood products. Most vaccinations can be given subcutaneously and this should be the preferred route. All routine childhood vaccinations should be given at the appropriate time. All patients with bleeding disorders should be vaccinated against hepatitis A and B. HIV positive patients should receive annual influenza vaccinations and should avoid the oral polio, oral typhoid, BCG and yellow fever vaccines.
引用
收藏
页码:541 / 546
页数:6
相关论文
共 13 条
[1]   Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients [J].
Breiman, RF ;
Keller, DW ;
Phelan, MA ;
Sniadack, DH ;
Stephens, DS ;
Rimland, D ;
Farley, MM ;
Schuchat, A ;
Reingold, AL .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (17) :2633-2638
[2]  
*CDCP, 1996, MMWR-MORBID MORTAL W, V45, P603
[3]   SAFETY OF INTRAMUSCULAR INJECTION OF HEPATITIS-B VACCINE IN HEMOPHILIACS [J].
EVANS, DIK ;
SHAW, A .
BRITISH MEDICAL JOURNAL, 1990, 300 (6741) :1694-1695
[4]   23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial [J].
French, N ;
Nakiyingi, J ;
Carpenter, LM ;
Lugada, E ;
Watera, C ;
Moi, K ;
Moore, M ;
Antvelink, D ;
Mulder, D ;
Janoff, EN ;
Whitworth, J ;
Gilks, CF .
LANCET, 2000, 355 (9221) :2106-2111
[5]   Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: Impact on plasma levels of HIV type 1 RNA and determinants of antibody response [J].
Fuller, JD ;
Craven, DE ;
Steger, KA ;
Cox, N ;
Heeren, TC ;
Chernoff, D .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (03) :541-547
[6]  
Halsey NA, 1999, PEDIATRICS, V103, P1057, DOI 10.1542/peds.103.5.1057
[7]   HIV-1 plasma viremia not increased in patients receiving highly active antiretroviral therapy after influenza vaccination [J].
Macías, J ;
Pineda, JA ;
Leal, M ;
Abad, MA ;
Delgado, J ;
Rosa, R ;
Rubio, A ;
Sánchez-Quijano, A ;
Lissen, E .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2001, 20 (01) :46-48
[8]  
PETER G, 1997, RED BOOK REPORT COMM, P348
[9]   Risk of hepatitis A virus infection in persons with hemophilia receiving plasma-derived products [J].
Richardson, LC ;
Evatt, BL .
TRANSFUSION MEDICINE REVIEWS, 2000, 14 (01) :64-73
[10]   Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1 [J].
Stanley, SK ;
Ostrowski, MA ;
Justement, JS ;
Gantt, K ;
Hedayati, S ;
Mannix, M ;
Roche, K ;
Schwartzentruber, DJ ;
Fox, CH ;
Fauci, AS .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (19) :1222-1230